Policy & Sector Insights

Fortune
The Trump administration has aimed a dagger at the heart of high pharmacy bills: the go-betweens in the supply chain that have been gouging insurers, drugmakers, and, most importantly, consumers…Read More.

The Ripon Advance
U.S. Reps. Greg Walden (R-OR) and Michael Burgess (R-TX) want details about whether the mega-mergers among Pharmacy Benefit Managers (PBMs) has contributed to rising national drug prices for the more than 266 million Americans using PBM prescription drug plans…Read More.

STAT
Now that states are moving to block pharmacy benefit managers from imposing “gag orders” on pharmacists, industry insiders and policymakers are sounding off louder than ever about the tendency for pharmacy benefit managers to extract value from the health system rather than add value to it…Read More.

The Columbus Dispatch
Rebates demanded by pharmacy middleman from drug manufacturers are driving up Americans’ prescription-drug costs by billions of dollars…Read More.

NPR
Several states are questioning the cost of using pharmacy middlemen to manage their prescription drug programs…Read More.

Pharm Pro
As the Trump Administration’s plan to lower the cost of prescription drugs continues to develop and unfold, transparency during rebate negotiation is emerging as a top priority…Read More.

CommonWealtht
Insurers use pharmacy benefits managers to tilt playing field…Read More.

Morning Consult
Few problems generate stronger emotions than the cost of drugs. President Donald Trump identified bringing down drug prices as a key priority in his campaign, and his administration…Read More.

Managed Care
The industry has been criticized for lack of transparency—and worse. Some see ‘a ton of sense’ in the proposed mergers with insurers and retailers. Others see a risk of even higher drug prices and a need for oversight…Read More.